339: RFK Jr.'s confirmation hearings, MASH drugs, and a controversial obesity ad
The Readout Loud
00:00
Advancements in MASH Treatment
This chapter explores the evolution of fatty liver disease terminology from NASH to MASH and discusses groundbreaking findings from Akiro Therapeutics regarding the potential reversal of cirrhosis in advanced MASH cases. It highlights the impact of GLP-1 medications and the newly approved drug ResDefra, emphasizing their implications for treatment options and clinical outcomes. The chapter concludes with insights into ongoing drug therapy developments targeting liver health and the importance of timely patient enrollment in clinical trials.
Transcript
Play full episode
